Lek Banned from Marketing Leading Drug in Croatia
Ljubljana, 1 October - Leading Slovenian pharmaceuticals company Lek will have to stop selling its drug Amlopin on the Croatian market, following the commercial court in Zagreb has issued a temporary order forbidding Lek's subsidiary Lek Zagreb to import and sell Amlopin in Croatia as of Friday, 4 October. Lek finds the order unfounded and is planning a complaint, the Ljubljana-based company has said, while no other details are known.
The rest of this news item is available to subscribers.
The news item consists of 375 characters (without spaces) or 71 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.